Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 601–700 of 1,000
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 42
“…disease (PD) is a chronic neurodegenerative disorder with cardinal motor symptoms of tremor, rigidity and bradykinesia, largely being attributed to a progressive loss of mesencephalic dopaminergic neurons located in the substantia nigra pars compacta (SNc) (Hirsch et al., 1988, Lees et al., 2009).”
BackgroundHain, E. G., Klein, C., Munder, T., Braun, J., Riek, K., Mueller, S. G., Sack, I., & Steiner, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161179 · Cited by 47
“The neurotoxin MPTP primarily affects dopaminergic neurons and is therefore an established animal model for the histopathology seen in PD patients [19,20].”
BackgroundChoi, D., Eun, J., Kim, B. G., Jou, I., Park, S. M., & Joe, E.-H. (2017) · Glia · doi:10.1002/glia.23258 · Cited by 44
Msibi, Z. N. P., & Mabandla, M. V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01059 · Cited by 41
Naoi, M., Maruyama, W., Yi, H. L., Yamaoka, Y., Shamoto‐Nagai, M., Akao, Y., Gerlach, M., Tanaka, M., & Riederer, P. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05329.x · Cited by 43
“In Parkinson’s disease (PD), dopaminergic and noradrenergic neurons are preferentially affected (Hirsch et al. 1988), and the presence of NM in most of these neurons suggests that NM may be involved in the cell vulnerability (Kastner et al. 1992).”
BackgroundKawaguchi, H., Shimada, H., Kodaka, F., Suzuki, M., Shinotoh, H., Hirano, S., Kershaw, J., Inoue, Y., Nakamura, M., Sasai, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151191 · Cited by 41
“As the selective loss of NM pigmented neurons occurs in the SN of PD patients [14], this suggests that NM-sensitive MRI can be used to track the progression of PD and as a marker of DA neuronal density in the SN.”
BackgroundWaeber, C., & Palacios, J. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90133-3 · Cited by 44
Elsworth, J. D., Deutch, A. Y., Redmond, D. E., Sladek, J. R., & Roth, R. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90474-p · Cited by 40
Clinical and pathological features in hydrocarbon‐induced Parkinsonism
Pezzoli, G., Strada, O., Silani, V., Zecchinelli, A., Perbellini, L., Javoy-Agid, F., Ghidoni, P., Motti, E., Masini, T., Scarlato, G., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400616 · Cited by 40
Self-citationStoof, J. C., Winogrodzka, A., Muiswinkel, F. L. V., Wolters, E. C., Voorn, P., Groenewegen, H. J., Booij, J., & Drukarch, B. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00260-5 · Cited by 44
Hunn, B. H. M., Vingill, S., Threlfell, S., Alegre-Abarrategui, J., Magdelyns, M., Deltheil, T., Bengoa-Vergniory, N., Oliver, P. L., Cioroch, M., Doig, N. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.029 · Cited by 38
González-Sepúlveda, M., Compte, J., Cuadros, T., Nicolau, A., Guillard-Sirieix, C., Peñuelas, N., Picón, M. L., Parent, A., Romero‐Giménez, J., Cladera-Sastre, J. M., et al. (2022) · Brain · doi:10.1093/brain/awac445 · Cited by 40
“of controls were used for the different quantifications: (1) the unaffected contralateral (nonAAV injected) hemisphere of each animal, representing an internal control/baseline; (2) a group of rats unilaterally injected with AAV-VMAT2 in the SN, which serve as a control of”
MethodTherapeutic strategies in Parkinson's disease: what we have learned from animal models
Valadas, J. S., Vos, M. H., & Verstreken, P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12577 · Cited by 45
Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity
Plotegher, N., Greggio, E., Bisaglia, M., & Bubacco, L. (2014) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583513000097 · Cited by 38
Shivers, K., Nikolopoulou, A., Machlovi, S. I., Vallabhajosula, S., & Figueiredo‐Pereira, M. E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.020 · Cited by 44
Tsui, A., & Isacson, O. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6061-6 · Cited by 42
“Likely to be a result of the extensive midbrain DA neuronal arborisation and large numbers of synaptic connections, PD symptoms only manifest after an estimated 70% of functional DA synapses are lost and intrastriatal DA concentrations have been reduced to less than 40% of its normal levels [ 7 , 63].”
BackgroundChemiexcitation and Its Implications for Disease
Brash, D. E., Goncalves, L. C. P., & Bechara, E. J. H. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.004 · Cited by 36
“A causal role for neuromelanin has long been suggested: The substantia nigra neurons lost in human postmortem samples are nearly exclusively those containing neuromelanin [87, 88].”
BackgroundCarmichael, K., Sullivan, B. T., Lopez, E., Sun, L., & Cai, H. (2021) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2021.07 · Cited by 52
“In addition, the SNc DANs are relatively more vulnerable to neuronal toxins in rodent PD models and preferentially degenerated in PD patients[25,26].”
BackgroundEmerging roles of growth differentiation factor‑15 in brain disorders (Review)
Jiang, W., Zhang, Z., He, P., Jiang, L., Chen, J.-Z., Zhang, X.-T., Hu, M., Zhang, Y.-K., & Ouyang, X.-P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10705 · Cited by 45
Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis
Ueno, F., Iwata, Y., Nakajima, S., Caravaggio, F., Rubio, J. M., Horga, G., Cassidy, C., Torres‐Carmona, E., Luca, V. D., Tsugawa, S., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.028 · Cited by 41
“In light of lower levels of NM pigmentation in the VTA compared to the SN in patients with Parkinson’s disease (Hirsch et al., 1988; Liang et al., 2004) and HCs (Wengler et al., 2020), NM levels in the VTA are originally lower than other brain regions.”
Capucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T. (2021) · Antioxidants · doi:10.3390/antiox10060824 · Cited by 36
“A typical neuropathological feature of PD is the presence of extracellular NM in the degenerating SN tissue [31], due to the conspicuous and selective death of pigmented dopaminergic neurons over the disease [32].”
BackgroundHuman IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity
Pamies, D., Wiersma, D., Katt, M. E., Zhao, L., Burtscher, J., Harris, G., Smirnova, L., Searson, P. C., Härtung, T., & Högberg, H. T. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105719 · Cited by 39
“, 2020) and their loss causes a lack of dopamine (DA) in the striatum (Lee et al., 1994; Hirsch et al., 1988).”
BackgroundKhan, M. S., Nasiripour, S., & Bopassa, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136416 · Cited by 57
Reserve pool neuron transmitter respecification: Novel neuroplasticity
Dulcis, D., & Spitzer, N. C. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20920 · Cited by 43
Lin, F., Gui, C., Wen, W., Bao, T., Zhang, X., & Wang, S. (2016) · Talanta · doi:10.1016/j.talanta.2016.05.062 · Cited by 37
α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
Butkovich, L. M., Houser, M. C., & Tansey, M. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00626 · Cited by 43
“Extensive dysfunction of catecholaminergic neurons is a well-established feature of PD, and a major hallmark is LP and loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) which induces motor impairments including tremor, muscle rigidity, bradykinesia, and postural instability (Hirsch et al.,…”
BackgroundBreysse, N., Carlsson, T., Winkler, C., Björklund, A., & Kirik, D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0626-07.2007 · Cited by 40
“In some moderate-to-severe Parkinson’s disease cases, however, neurodegeneration is more widespread and will involve also the dorsal tier neurons and the VTA (Hirsch et al., 1988; Damier et al., 1999).”
BackgroundMani, V., Devasenathipathy, R., Chen, S., et al. (2015) · International Journal of Electrochemical Science · doi:10.1016/s1452-3981(23)05065-4 · Cited by 37
Inflammation in parkinson’s disease: Causative or epiphenomenal?
Hald, A., van Beek, J., & Lotharius, J. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_12 · Cited by 37
Cysteinyldopamine is not incorporated into neuromelanin
Wakamatsu, K., Ito, S., & Nagatsu, T. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90336-r · Cited by 37
Flies with Parkinson's disease
Vanhauwaert, R., & Verstreken, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.02.020 · Cited by 39
Graphene–Metal Oxide Nanocomposite Modified Electrochemical Sensors
Immanuel, S., Aparna, T. K., & Sivasubramanian, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-815394-9.00005-4 · Cited by 37
Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity
Lawana, V., Um, S. Y., Rochet, J., Turesky, R. J., Shannahan, J. H., & Cannon, J. R. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz210 · Cited by 38
“In contrast, neurons with higher neuromelanin content are more susceptible to cell death (Gibb, 1992; Hasegawa, 2010; Hirsch et al., 1988; Mann and Yates, 1983).”
BackgroundVerma, A., & Ravindranath, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00382 · Cited by 42
Alosaimi, F., Boonstra, J. T., Tan, S. K. H., Temel, Y., & Jahanshahi, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998932 · Cited by 41
“Additionally, PD exhibits a neuropathological vulnerability to neuromelanin loss that is shown to affect both DA in the SNc and NA in the LC (Hirsch et al., 1988; Sasaki et al., 2006; Ohtsuka et al., 2013; MartinBastida et al., 2017; Singh, 2020).”
BackgroundRibeiro, F. M., Pires, R. G. W., Ferreira, T. A. A., Presti‐Silva, S. M., & Simões, A. T. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360264 · Cited by 44
“PD is characterized primarily by motor impairments such as tremor, rigidity, and bradykinesia, as a result of a complex mechanism that involves a slow and progressive loss of nigrostriatal dopaminergic neurons (Hirsch et al., 1988).”
BackgroundDetrimental deletions: mitochondria, aging and Parkinson's disease
Biskup, S., & Moore, D. J. (2006) · BioEssays · doi:10.1002/bies.20471 · Cited by 39
Ueda, S., Aikawa, M., Ishizuya‐Oka, A., Yamaoka, S., Koibuchi, N., & Yoshimoto, K. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00451-0 · Cited by 36
Mechanism and consequences of nerve cell death in Parkinson’s disease
Hirsch, É. C. (1999) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6360-3_7 · Cited by 40
Substantia Nigra and Locus Coeruleus
Halliday, G. M. (2004) · Elsevier eBooks · doi:10.1016/b978-012547626-3/50015-6 · Cited by 43
Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism
Chougar, L., Arsovic, E., Gaurav, R., Biondetti, E., Faucher, A., Valabrègue, R., Pyatigorskaya, N., Dupont, G., Lejeune, F., Cormier‐Dequaire, F., et al. (2022) · Movement Disorders · doi:10.1002/mds.28988 · Cited by 38
“In PD, degeneration predominated in the posterolateral part of the caudal SN as shown in histological 4,19,40,41 and MRI studies.”
Neurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives
Mohamed, W. M. Y., Kumar, J., Alghamdi, B. S. A., Wadan, A.-H. S., & Yamashita, T. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.12.003 · Cited by 42
Solano, F., Hearing, V. J., & García-Borrón, J. C. (1999) · Neurotoxicity Research · doi:10.1007/bf03033287 · Cited by 39
Ferraz, A. C., Matheussi, F., Szawka, R. E., Rizelio, V., Delattre, A. M., Rigon, P., Hermel, É. D. E. S., Xavier, L. L., Achaval, M., & Anselmo-Franci, J. A. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9575-7 · Cited by 35
Chung, C. Y., Koprich, J. B., Endo, S., & Ole Isacson, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1972-07.2007 · Cited by 39
“Regardless of specific etiology, DA neurons in the A9 region [substantia nigra (SN)] are considerably more vulnerable than DA neurons in the adjacent A10 region [ventral tegmental area (VTA)] (Hirsch et al., 1988).”
WYLIE, D. R. W., Lau, K. L., Lu, X., Glover, R. G., & Valsangkar-Smyth, M. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991025)413:3<480::aid-cne9>3.0.co;2-j · Cited by 14
Deutch, A. Y., Rosin, D. L., Goldstein, M., & Roth, R. H. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90166-0 · Cited by 35
Zhang, P., Damier, P., Hirsch, É. C., Agid, Y., Ceballos-Picot, I., Sinet, P., Nicole, A., Laurent, M., & Javoy-Agid, F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90463-p · Cited by 39
Self-citationChiueh, C. C., Murphy, D. L., MIYAKE, H., Lang, K., Tulsi, P., & Huang, S. J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb18324.x · Cited by 36
The Use of Stem Cells in Regenerative Medicine for Parkinson's and Huntington's Diseases
Lescaudron, L., Naveilhan, P., & Neveu, I. (2012) · Current Medicinal Chemistry · doi:10.2174/0929867311209066018 · Cited by 35
Lee, J., Kim, S. W., & Kim, K.-T. (2022) · Cells · doi:10.3390/cells11121902 · Cited by 34
Ghanbari, K., & Hajheidari, N. (2015) · Journal of Polymer Research · doi:10.1007/s10965-015-0797-0 · Cited by 34
Hydrogen Sulfide and Neuroinflammation
Kida, K., & Ichinose, F. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-18144-8_9 · Cited by 37
Nucleotide excision repair in chronic neurodegenerative diseases
Sepe, S., Payán‐Gómez, C., Milanese, C., Hoeijmakers, J. H. J., & Mastroberardino, P. G. (2013) · DNA repair · doi:10.1016/j.dnarep.2013.04.009 · Cited by 38
Schroeder, R. L., Double, K. L., & Gerber, C. (2015) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2015.02.001 · Cited by 41
Henry, V., Paillé, V., Lelan, F., Brachet, P., & Damier, P. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181b767b4 · Cited by 38
“The postmortem observation of TH-negative cells containing neuromelanin, a pigment typical of dopaminergic cells in human SNpc of advanced PD patients and not in controls, suggests a similar chronology in the human disease (51).”
ResultEffect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
Carvalho, M. M., Campos, F. L., Marques, M., Soares‐Cunha, C., Kokras, N., Dalla, C., Leite‐Almeida, H., Sousa, N., & Salgado, A. J. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00145 · Cited by 42
“Parkinson’s disease (PD) is a chronic neurodegenerative disorder affecting the dopaminergic system, causing significant neuronal loss in the substantia nigra pars compacta (SNc, or A9), and in the ventral tegmental area (VTA, or A10; Hirsch et al., 1988; German et al., 1989; Parkinson, 2002), and characterized by a nu…”
BackgroundGerlach, M., Riederer, P., & Double, K. L. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.028 · Cited by 33
Kim, T. W., Moon, Y., Kim, K., Lee, J. E., Koh, H. C., Rhyu, I. J., Kim, H., & Sun, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025346 · Cited by 36
“bradykinesia [1,2,3,4].”
Putaminal Mosaic Visualized by Tyrosine Hydroxylase Immunohistochemistry in the Human Neostriatum
Morigaki, R., & Goto, S. (2016) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00034 · Cited by 37
“Parkinson’s disease (PD) results from a striatal dopamine deficiency due to the neurodegenerative Frontiers in Neuroanatomy | www.frontiersin.org 1 April 2016 | Volume 10 | Article 34 loss of dopamine-producing cells in the substantia nigra pars compacta (SNc; Hirsch et al., 1988).”
BackgroundMesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease
Geibl, F. F., Henrich, M. T., & Oertel, W. H. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01970-9 · Cited by 40
Heterogeneity of dopamine release sites in health and degeneration
Lebowitz, J. J., & Khoshbouei, H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104633 · Cited by 36
The Nigrostriatal Pathway: Axonal Collateralization and Compartmental Specificity
Prensa, L., Giménez‐Amaya, J. M., Parent, A., Bernácer, J., & Cebrián, C. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_4 · Cited by 36
“These neurons contain neuromelanin pigments and degenerate massively in sporadic PD (Hirsch et al. 1988).”
BackgroundTransforming Growth Factor β Cooperates with Persephin for Dopaminergic Phenotype Induction
Roussa, E., Oehlke, O., Rahhal, B., Heermann, S., Heidrich, S., Wiehle, M., & KRIEGLSTEIN, K. G. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0805 · Cited by 34
Shaw, V. E., Keay, K. A., Ashkan, K., Benabid, A. L., & Mitrofanis, J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.02.008 · Cited by 35
DJ-1 interacts with RACK1 and protects neurons from oxidative-stress-induced apoptosis
Ma, J., Wu, R., Zhang, Q., Wu, J., Lou, J., Zheng, Z., Ding, J., & Yuan, Z. (2014) · Biochemical Journal · doi:10.1042/bj20140235 · Cited by 34
Ferrari, E., Engelen, M., Monzani, E., Sturini, M., Girotto, S., Bubacco, L., Zecca, L., & Casella, L. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0951-7 · Cited by 38
Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields
Halliday, G. M., Reyes, S., & Double, K. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374236-0.10013-6 · Cited by 43
Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system
Smits, S. M., Mathon, D. S., Burbach, J. P. H., Ramakers, G. M. J., & Smidt, M. P. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.07.018 · Cited by 33
Huang, X., Xu, R., Hawley, M. D., Hopkins, T. L., & Kramer, K. J. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0567 · Cited by 34
Iannitelli, A. F., & Weinshenker, D. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105287 · Cited by 37
Depboylu, C., Höllerhage, M., Schnurrbusch, S., Brundin, P., Oertel, W. H., Schrattenholz, A. S., & Höglinger, G. U. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.10.050 · Cited by 36
Ismail, I., Okajima, T., Kawauchi, S., & Ohsaka, T. (2016) · Electrochimica Acta · doi:10.1016/j.electacta.2016.05.056 · Cited by 32
Corwin, C., Nikolopoulou, A., Pan, A. L., Nunez-Santos, M., Vallabhajosula, S., Serrano, P. A., Babich, J. W., & Figueiredo-Pereira, M. E. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1305-3 · Cited by 34
H2S-based fluorescent imaging for pathophysiological processes
Jia, T.-T., Zhang, Y., Hou, J., Niu, H., & Wang, S. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1126309 · Cited by 33
“Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra (SN) (Hirsch et al., 1988).”
BackgroundDouble, K. L., & Halliday, G. M. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_19 · Cited by 31
“In fact a direct correlation was reported between cell loss in the individual cell groups which make up the SN and the percentage of NM-positive cells found in them (Hirsch et al., 1988).”
BackgroundMarutani, E., Sakaguchi, M., Chen, W., Sasakura, K., Liu, J., Xian, M., Hanaoka, K., Nagano, T., & Ichinose, F. (2014) · MedChemComm · doi:10.1039/c4md00180j · Cited by 32
Survival of Dopaminergic Amacrine Cells after Near-Infrared Light Treatment in MPTP-Treated Mice
Peoples, C. L., Shaw, V. E., Stone, J., Jeffery, G., Baker, G. E., & Mitrofanis, J. (2012) · ISRN Neurology · doi:10.5402/2012/850150 · Cited by 35
Keber, U., Klietz, M., Carlsson, T., Oertel, W. H., Weihe, E., Schäfer, M. K.-H., Höglinger, G. U., & Depboylu, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.021 · Cited by 33
“, 1973), resulting from a progressive loss of terminals of degenerating neuromelanin-containing DAergic neurons in the substantia nigra pars compacta (SNpc) (Hirsch et al., 1988).”
Meurers, B. H., Zhu, C., Fernagut, P., Richter, F., Hsia, Y.-C., Fleming, S. M., Oh, M., Elashoff, D. A., DiCarlo, C. D., Seaman, R. L., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.001 · Cited by 35
“Although many neuronal populations are affected in Parkinson disease (PD), dopaminergic (DA) neurons in the substantia nigra pars compacta (SNC) are among the most severely affected and their death leads to major neurological disability (Hirsch et al., 1988; Fearnley and Lees, 1991).”
BackgroundSpasojević, I., Mojović, M., Stević, Z., Spasić, S. D., Jones, D. R., Morina, A., & Spasić, M. B. (2010) · Redox Report · doi:10.1179/174329210x12650506623087 · Cited by 32
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 34
“Parkinson’s disease (PD) is widely attributed to progressive neurodegeneration of dopaminergic neurons in the substantia nigra (Hirsch et al., 1988; Olanow and Tatton, 1999).”
RetractedLi, J., Scheller, C., Koutsilieri, E., Griffiths, F., Beart, P. M., Mercer, L. D., Halliday, G., Kettle, E., Rowe, D., Riederer, P., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03404.x · Cited by 32
“The pigmentation found within the dopaminergic SN is suggested to underlie the especial vulnerability of NM-containing dopaminergic cells in Parkinson’s disease (Hirsch et al. 1988); thus this pigment is of particular interest.”
BackgroundTyrosinase enhances the covalent modification of DNA by dopamine
Stokes, A. H., Brown, B. G., Lee, C. K., Doolittle, D. J., & Vrana, K. E. (1996) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00164-7 · Cited by 32
Three-dimensional measurement of essential tremor
Matsumoto, J. Y., Dodick, D. W., Stevens, L. N., Newman, R. C., Caskey, P. E., & Fjerstad, W. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2<288::aid-mds1014>3.0.co;2-m · Cited by 34
Current theories on the cause of Parkinson's disease.
Langston, J. W. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.suppl.13 · Cited by 32
“While most substances in the brain decline with normal aging, MAO B (but not A) has been shown, both in rodents'6 and primates,'7 including the human,'8 to increase with aging.”
BackgroundSmits, S. M., von Oerthel, L., Hoekstra, E. J., Burbach, J. P. H., & Smidt, M. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076037 · Cited by 31
Belloso-Iguerategui, A., Zamarbide, M., Merino-Galán, L., Rodríguez-Chinchilla, T., Gago, B., Santamaría, E., Fernández‐Irigoyen, J., Cotman, C. W., Prieto, G. A., Quiroga‐Varela, A., et al. (2023) · Brain · doi:10.1093/brain/awad227 · Cited by 34
“56 However, no studies have as yet been undertaken at the earliest stages of the disease.”
BackgroundTian, L., Karimi, M., Loftin, S. K., Brown, C., Xia, H. C., Xu, J., Mach, R. H., & Perlmutter, J. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031439 · Cited by 34
“deficiency produces the major motor manifestations of idiopathic PD [1,2].”
BackgroundGhanemi, A. (2013) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2013.03.005 · Cited by 34
“3% of the entire population,(33) is characterized by movement disorder resulting essentially from neurolysis affecting dopaminergic neurons in the substantia nigra pars compacta (SNpc).(34) Furthermore several neuro-structures, such as anterior olfactory structures, amygdala, dorsal motor nucleus of vagus, caudal raph…”
BackgroundThe dopamine transporter is differentially regulated after dopaminergic lesion
Afonso‐Oramas, D., Cruz‐Muros, I., Barroso‐Chinea, P., de la Rosa, D. Á., Castro‐Hernández, J., Salas-Hernández, J., Giráldez, T., & González‐Hernández, T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.012 · Cited by 35
“Bearing in mind the functional division of the mesostriatal system (Fallon and Moore, 1978; Joel and Weiner, 2000) and the degeneration pattern in PD (Bernheimer et al., 1973; Damier et al., 1999; Hirsch et al., 1988) and in our rat model of PD, the midbrain DAformation was divided into three regions: (1) the SNcv, wh…”
BackgroundCurrent and emerging therapeutic targets for Parkinson’s disease
Pingale, T. D., & Gupta, G. L. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00636-w · Cited by 32
Pessiglione, M., Guehl, D., Jan, C., François, C., Hirsch, É. C., Féger, J., & Tremblay, L. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03089.x · Cited by 40
A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death
Farzam, A., Chohan, K. L., Strmiskova, M., Hewitt, S. J., Park, D. S., Pezacki, J. P., & Özcelik, D. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101377 · Cited by 34
Lehéricy, S., Brandel, J., Hirsch, É. C., Anglade, P., Villares, J., Scherman, D., Duyckaerts, C. J., Javoy-Agid, F., & Agid, Y. (1994) · Brain Research · doi:10.1016/0006-8993(94)90856-7 · Cited by 35
“The reduction in density of 3H-TBZOH binding sites in the striatum of PD patients is consistent with the dopaminergic cell loss in the mesencephalon [18,26,31,34].”
BackgroundResultInfluentialSelf-citationα-synuclein and Parkinson’s disease: a proteomic view
Fasano, M., & Lopiano, L. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.239 · Cited by 35
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates
Chocarro, J., Rico, A. J., Ariznabarreta, G., Roda, E., Honrubia, A., Collantes, M., Peñuelas, I., Vázquez, A., Rodriguez-Perez, A. I., Labandeira-García, J. L., et al. (2023) · Brain · doi:10.1093/brain/awad331 · Cited by 30
“These series were used for (1) direct NMel visualization, (2) immunoperoxidase detection of TH, (3) dual immunofluorescent detection of tyrosine hydroxylase (TH) and P62 combined with brightfield visualization of NMel, (4) triple immunofluorescent detection of α-Syn, TH and”
MethodA Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells
Patil, K. S., Basak, I., Pal, R., Ho, H., Alves, G. W., Chang, E. J., Larsen, J. P., & Møller, S. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143969 · Cited by 30
“Parkinson’s disease (PD) is the most common neurodegenerative movement disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta [1].”
BackgroundJang, S. E., Qiu, L., Chan, L. L., Tan, E., & Zeng, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.558532 · Cited by 35
“More importantly, A9 neurons display significantly enhanced levels of neuromelanin pigmentation as compared to other dopamine-producing neurons (Mann and Yates, 1983; Hirsch et al., 1988; Gibb, 1992; Kastner et al., 1992).”
BackgroundCharting human subcortical maturation across the adult lifespan with in vivo 7 T MRI
Miletić, S., Bazin, P., Isherwood, S. J., Keuken, M. C., Alkemade, A., & Forstmann, B. U. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118872 · Cited by 34
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.